Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intermittent sunitinib in advanced solid tumors
NL-OMON44759Phase 1Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sunitinib in Nonhematologic neoplasms (3 arms), sponsored by Vrije University Medical Center. Primary endpoints: Maximum tolerated dose, Safety and tolerability and 1 more. Started Jul 2013; status: active, not recruiting.
02
Drugs
sunitinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON44759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44759.